Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo as 1L Therapy for Metastatic NSCLC of PD-L1 TPS >= 50%: KEYNOTE-598 - (:unkn) unknown (ELSEVIER SCIENCE INC, 2021)
Keywords: Phase III trial; Relapsed Malignant Mesothelioma; Immune-checkpoint-inhibitor